Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells

Hongyan Jian,1 Xing Shen,1 Irwin Liu,1 Mikhail Semenov,2 Xi He,2 and Xiao-Fan Wang1,3
1Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA; 2Division of Neuroscience, Children’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA

Adult mesenchymal stem cells (MSCs) derived from bone marrow contribute to the regeneration of multiple types of mesenchymal tissues. Here we describe the functional role of a novel form of cross-talk between the transforming growth factor β1 (TGF-β1) and Wnt signaling pathways in regulating the activities of human MSCs. We show that TGF-β1 induces rapid nuclear translocation of β-catenin in MSCs in a Smad3-dependent manner. Functionally, this pathway is required for the stimulation of MSC proliferation and the inhibition of MSC osteogenic differentiation by TGF-β1, likely through the regulation of specific downstream target genes. These results provide evidence for a new mode of cooperation between the TGF-β and Wnt signaling pathways in this specific cellular context and suggest a potentially important role for this distinct signaling pathway in the control of self-renewal and differentiation of a specific type of MSCs.

[Keywords: Human mesenchymal stem cells; TGF-β1; β-catenin]

Supplemental material is available at http://www.genesdev.org.

Received October 27, 2005; revised version accepted January 25, 2006.
certain developmental events in *Xenopus* and *Drosophila*. This cooperative regulation is mediated by the association between Smads and TCF/LEF in the nucleus, and results in the synergistic activation of specific target genes (Labbe et al. 2000; Nishita et al. 2000). In this report, we demonstrate a novel level of cross-talk between TGF-β and Wnt signaling pathways in MSCs derived from adult human bone marrow, and this cross-talk may play an important role in regulating self-renewal and differentiation programs of those MSCs.

**Results**

*TGF-β1 induces nuclear translocation of β-catenin without affecting the steady-state protein level of β-catenin and independent of canonical Wnt signaling pathway*

In an attempt to explore the regulatory mechanisms that govern the proliferation and differentiation programs of human MSCs, we investigated the cross-talk between TGF-β and Wnt signaling pathways in this specific cellular context. To do this, we stimulated primary MSCs that were derived from adult human bone marrow with either Wnt3A or TGF-β1. As shown in Figure 1A, a significant amount of β-catenin appeared in the nucleus of MSCs after 2 h incubation with Wnt3A-conditioned medium as determined by nuclear/cytoplasmic fractionation. To our surprise, we found that TGF-β1 was also capable of inducing the nuclear translocation of β-catenin in a manner similar to Wnt3A treatment, since an increasing amount of β-catenin was detected in the nuclear fraction 1–2 h after the cells were treated with TGF-β1 [Fig. 1A]. To verify this highly intriguing result, we used immunofluorescence imaging to directly visualize the localization of β-catenin. As shown in Figure 1B, the nuclear staining of endogenous β-catenin was significantly increased in MSCs 1 h after treatment with TGF-β1, confirming the data from the fractionation experiments. When MSCs were plated at a low cell density to maintain their undifferentiated state, strong staining containing conditioned medium for 6 h before TGF-β1 treatment for 2 h. Nuclear fractions of β-catenin were detected by anti-β-catenin antibody. [I] The levels of nuclear β-catenin in vector control and DVL-ΔPDZ adenovirus-infected MSCs treated with TGF-β1 for 2 h were determined by Western blot analysis.
of β-catenin in the nucleus was detected in >90% of the cells following treatment with TGF-β1. Importantly, β-catenin accumulation in the nucleus was rapid in response to TGF-β1 treatment, suggesting that the TGF-β1-induced β-catenin nuclear translocation in MSCs is likely to be mechanistically distinct from that of the slow accumulation of β-catenin in the nucleus in response to TGF-β1 as previously reported in the context of chondrogenesis of MSCs (Tuli et al. 2003; Zhou et al. 2004). To determine whether the ability of TGF-β1 to induce β-catenin nuclear translocation was cell-type specific, we examined β-catenin localization upon TGF-β1 treatment in Madin-Darby canine kidney (MDCK) epithelial cells. Although Wnt3A treatment increased nuclear β-catenin levels in MDCK cells, TGF-β1 treatment did not (Fig. 1C,D). Taken together with the observations that TGF-β1 failed to induce rapid nuclear accumulation of β-catenin in HaCaT human keratinocytes and BJ human fibroblasts (data not shown), these results suggest that β-catenin nuclear translocation in response to TGF-β1 may be associated specifically with certain cellular contexts such as MSCs.

Wnt-induced nuclear accumulation of β-catenin has been established in multiple cellular systems as the consequence of β-catenin stabilization (Orford et al. 1997). To determine whether TGF-β1 induces β-catenin nuclear translocation via a similar mechanism, we measured the steady-state protein levels of β-catenin in MSCs in the presence or absence of TGF-β1 proteasome inhibitors. Interestingly, no change in the levels of β-catenin was observed after the MSCs were treated with TGF-β1 for 24 h (Fig. 1E) or three different types of proteasome inhibitors (Supplementary Fig. 1), suggesting that β-catenin nuclear translocation in response to TGF-β1 is not mediated by a significant change in the stability of β-catenin in MSCs. As a control, Wnt3A treatment still induced an increase in β-catenin protein levels in this cellular context (Fig. 1E).

Since the expression of several members of the Wnt family is known to be regulated by TGF-β1 (Zhou et al. 2004), β-catenin nuclear translocation in response to TGF-β1 could be a consequence of TGF-β1-induced Wnt production and action through an autocrine mechanism. To test this possibility, we pretreated MSCs with the protein translation inhibitor cycloheximide (CHX) before the addition of TGF-β1. As shown in Figure 1F, the presence of CHX did not have an effect on the ability of TGF-β1 to induce β-catenin nuclear accumulation, even though the induction of a TGF-β1 target gene plasminogen activator inhibitor-1 (PAI-1) was completely blocked (Fig. 1G), suggesting that this novel activity of TGF-β1 is not mediated by an increase in the production of Wnt proteins. Again, no significant changes in the levels of total β-catenin protein were detected under the same conditions of CHX treatment (Fig. 1G). This result, together with those derived from treatment of proteasome inhibitors (Supplementary Fig. 1), indicates that β-catenin is highly stable in MSCs. To explore whether TGF-β1 induced nuclear translocation of β-catenin required Wnt signaling, we used a competitive inhibitor of the Wnt receptor Frizzled, Fz8CRD (Hsieh et al. 1999). As shown in Figure 1H, addition of Fz8CRD to the culture medium of MSCs had no effect on TGF-β1-stimulated β-catenin nuclear translocation, even though the same treatment blocked the nuclear accumulation of β-catenin induced by Wnt3A (Supplementary Fig. 2). This result suggests that the observed β-catenin nuclear translocation in response to TGF-β1 is unlikely a Wnt ligand-dependent process. To further address this question, we used a dominant-negative form of disheveled (DVL-ΔPDZ), whose ectopic expression was shown to disrupt Wnt signaling (Hino et al. 2003). As a positive control, the adenovirus-mediated expression of DVL-ΔPDZ was able to inhibit the ability of Wnt3A to stabilize β-catenin in C57MG cells (Supplementary Fig. 2). However, DVL-ΔPDZ expression did not block the translocation of β-catenin in response to TGF-β1 [Fig. 1I]. These results indicate that TGF-β1-induced β-catenin nuclear translocation does not require the canonical Wnt signaling pathway involving β-catenin dephosphorylation and stabilization.

β-catenin nuclear translocation is mediated by the TGF-β signaling pathway

To explore the mechanism by which TGF-β1 induces β-catenin nuclear translocation, we next examined whether nuclear translocation of β-catenin is dependent on the signaling activity of the TGF-β type I receptor. To probe this, we pretreated MSCs with an inhibitor of the TGF-β type I receptor kinase, SD208 (Uhl et al. 2004), for 30 min before applying TGF-β1 treatment for another hour. Not only did SD208 block the phosphorylation of Smad2 [Fig. 2A], demonstrating that SD208 effectively inhibited TGF-β1 signaling, it also inhibited the nuclear translocation of β-catenin [Fig. 2B]. These data indicate that TGF-β1-induced nuclear translocation of β-catenin was mediated by the bona fide TGF-β signaling pathway via the activation of the type I receptor kinase.

To further explore this mechanism, we investigated whether the primary effectors of TGF-β signaling, the Smads, are directly involved in the process of β-catenin nuclear translocation. To do this, we evaluated the effect of Smad3 knockdown on the ability of TGF-β1 to induce β-catenin nuclear translocation. By introducing a Smad3-specific small interfering RNA [siRNA] construct into MSCs through retroviral transfer, the expression of Smad3 protein was reduced by >90% [Fig. 2C]. Subsequently, we examined β-catenin nuclear translocation in response to TGF-β1 in MSCs stably expressing the Smad3-siRNA in comparison with those infected with a retroviral vector control. As shown in Figure 2D, the cell fractionation results clearly indicate that Smad3 is required for the TGF-β1-induced nuclear translocation of β-catenin, since the amount of β-catenin in the nuclear fraction was barely detectable in MSCs with reduced expression of Smad3. This result also indicates that Smad2 may not be involved in the mediation of TGF-β1-induced nuclear translocation of β-catenin. Importantly,


under the same conditions, Wnt3A treatment could still increase the level of β-catenin in the nucleus (Fig. 2D), suggesting that the mechanism of Wnt3A-induced β-catenin nuclear accumulation in MSCs is distinct from that of TGF-β1-induced β-catenin nuclear translocation.

The requirement of Smad3 for β-catenin nuclear translocation suggests the possibility that Smad3 could actively transport β-catenin into the nucleus. Previous reports have shown that Smad3 can interact with β-catenin and its binding partners Axin and CKIε (Labbe et al. 2000; Furuhashi et al. 2001; Waddell et al. 2004). Thus, it is possible that Smad3 and β-catenin coexist in a complex in the cytoplasm, then translocate into the nucleus simultaneously upon TGF-β1 stimulation. Consistent with this postulation, we found that Smad3 and β-catenin were indeed in the same complex in MSCs, since endogenous β-catenin and Smad3 could be coimmunoprecipitated by an anti-Smad3 antibody, and this interaction was minimally affected by TGF-β1 (Fig. 2E). Furthermore, endogenous Smad3 was found to interact with GSK-3β (Fig. 2F), another protein known to be associated with β-catenin. Interestingly, the association between Smad3 and GSK-3β decreases in response to TGF-β (Fig. 2F). Attempts to detect association between Smad3 and Axin or CKIε were unsuccessful, possibly because of the low levels of endogenous Axin or CKIε. Nevertheless, taken together with previous findings that both Smad3 and β-catenin could interact with Axin/CKIε and the association between Smad3 and Axin/CKIε decreases in response to TGF-β in cell types other than MSCs (Furuhashi et al. 2001; Waddell et al. 2004), these results support a model in which the nuclear translocation of β-catenin in response to TGF-β1 can be directly linked to changes in the composition and dynamics of a protein complex possibly containing β-catenin, Smad3, GSK-3β, Axin, and CKIε.

**β-catenin mediates TGF-β activity in hMSCs**

**Figure 2.** β-catenin nuclear translocation is mediated by the TGF-β signaling pathway. (A) Whole-cell lysates of MSCs untreated or treated with TGF-β1 and the type I TGF-β receptor inhibitor SD208 for 30 min were blotted with a polyclonal antiphospho-Smad2 antibody. (B) Nuclear fractions of MSCs untreated or treated with TGF-β1 and SD208 were detected by anti-β-catenin antibody. The concentrations of SD208 used in this assay were 50 and 100 nM. (C) MSCs were infected with control (pRS) or Smad3 siRNA (pRS-Smad3) expressing retrovirus and selected by puromycin. Whole-cell lysates from stable cell populations were blotted with an anti-Smad3 rabbit polyclonal antibody. Equal loading was confirmed by the presence of β-catenin. (D) Nuclear fractions from pRS or pRS-Smad3 retrovirus-infected MSCs untreated or treated with TGF-β1 for 2 h or Wnt3A for 6 h were blotted with the anti-β-catenin antibody. (E) Whole-cell lysates from MSCs untreated or treated with TGF-β1 for 1 or 2 h were subjected to immunoprecipitation with an anti-Smad3 polyclonal antibody. An anti-Flag antibody was used as the Ab control for the immunoprecipitation. The Western blots were carried out using antibodies against β-catenin. (IP) Immunoprecipitation, (IB) immunoblotting. (F) Immunoprecipitation was performed as in E with lysates from MSCs untreated or treated with TGF-β for 2 h. GSK-3β was detected by a mouse monoclonal antibody.

**TGF-β1 and nuclear β-catenin exert similar biological effects on MSCs**

To investigate whether activation of this novel Smad3/β-catenin-mediated TGF-β1 signaling pathway is associated with a specific biological response in MSCs, we examined the effects of TGF-β1 on the regulation of proliferation and osteogenic differentiation in MSCs. As shown in Figure 3A and Supplementary Figure 3, TGF-β1 stimulated the proliferation of MSCs, an activity that contrasts the potent antiproliferative effect of TGF-β1 on many other cell types (Massague 1998). To determine whether TGF-β1 could also affect the differentiation program of these MSCs, an osteogenic assay was performed to measure the production of alkaline phosphatase (ALP) by culturing the MSCs in the osteogenic supplemental (OS) medium in the presence or absence of TGF-β1. In the absence of TGF-β1, an expected enhancement in the staining of ALP was observed in MSCs driven toward osteogenic differentiation by the culturing of those cells in OS medium (Fig. 3B). In contrast, the presence of TGF-β1 in the OS medium resulted in a much lower level of ALP staining (Fig. 3B), suggesting that TGF-β1 inhibits the osteogenic effect of the OS medium on MSCs.

We then tested the postulation that nuclear translocation of β-catenin was directly linked to the TGF-β1-mediated regulation of proliferation and osteogenic differentiation of MSCs. To begin, we evaluated the effects of nuclear accumulation of β-catenin on the activities of MSCs by the introduction of a mutant form of β-catenin into those cells via retroviral infection. This β-catenin mutant retains full transcriptional activity but contains
alanine substitutions at the four serine phosphorylation sites to prevent it from ubiquitination-mediated degradation [Barth et al. 1999]. Interestingly, the ectopically expressed mutant form of β-catenin was almost completely localized in the nucleus of MSCs (Fig. 3C), in contrast to the previously reported predominant cell–cell junction localization of this same mutant at the plasma membrane [Barth et al. 1999]. Similar to the proliferative effect of TGF-β1, expression of this β-catenin mutant in MSCs led to a significant increase in proliferation when compared with control cells [Fig. 3D]. Consistent with the antiosteogenic effect of TGF-β1 in the MSCs, expression of this β-catenin mutant caused a substantial decrease in ALP staining [Fig. 3E]. These results suggest that nuclear-localized β-catenin could exert similar biological effects on MSCs as those of TGF-β1, strongly supporting the postulation that there is a direct correlation between the activation of the Smad3/β-catenin-mediated TGF-β1 signaling pathway and the elicitation of unique biological responses in MSCs.

**Nuclear β-catenin is required for the primary effects of TGF-β1 on MSCs through regulation of specific downstream target genes.**

To further test this hypothesis, we next attempted to reduce the expression of β-catenin by using the siRNA strategy that was reported in a previous study [van de Wetering et al. 2003]. However, this approach was unsuccessful due to the relatively high stability of β-catenin protein in this specific cell type [Fig. 1G, Supplementary Fig. 1]. Consequently, we resorted to the use of a C-terminal truncation mutant of LEF1, LEF1ΔC, which lacks the HMG box and the nuclear localization sequence B box [Prieve et al. 1996]. As a transcription factor, the wild-type LEF1 is known to reside on specific promoter sequences of Wnt-responsive genes and form a complex with β-catenin via a domain located in the N-terminal region of LEF1 to activate transcription after β-catenin translocates into the nucleus [Logan and Nusse 2004]. In addition, the HMG box of LEF1 was shown to mediate the interaction between LEF1 and Smad3 in the context of synergistic activation of specific target genes by the two transcription factors [Labbe et al. 2000]. Thus, this mutant form of LEF1 is expected to retain β-catenin in the cytoplasm, since its ability to interact with β-catenin through its N-terminal region should be unaltered, consequently acting as a dominant-negative inhibitor that prevents the nuclear translocation of β-catenin without affecting the movement of Smad3. Consistent with this prediction, LEF1ΔC maintained its ability to interact with β-catenin in a similar fashion as that of the wild-type protein, but was unable to associate with Smad3 [Fig. 4A,B]. When LEF1ΔC was introduced into the MSCs via an adenoviral delivery system [He et al. 1998], its expression was found to be mainly restricted in the cytoplasm [Fig. 4C]. Under this condition, TGF-β was unable to induce β-catenin translocation to the nucleus, in contrast to that in cells infected with the control adenovirus [Fig. 4D]. Most importantly, TGF-β-induced cell proliferation was significantly inhibited by the expression of LEF1ΔC in MSCs [Fig. 4E], strongly suggesting that the stimulatory effect of TGF-β1 on MSCs proliferation is mediated by this
The treatment of TGF-β1 for 2 h. Under such conditions, we infected MSCs with or without the LEF1 analysis on RNA samples isolated from vector control or signaling pathway in MSCs, we carried out microarray translocation of TGF-β1 on osteogenic differentiation of MSCs. Eliminated the inhibitory effect of TGF-β1 on proliferation of MSCs in culture. Additionally, we found that expression of LEF1 mediated TGF-β1-induced modulation in response of these genes does not require nuclear β-catenin. We further verified the expression profile of BLK and BAX in response to TGF-β1 in the vector control and LEF1ΔC-expressing cells by real-time...
PCR. As shown in Figure 4, G and H, BLK expression was unable to be induced by TGF-β1 in LEF1ΔC-expressing cells, whereas the expression of BAX was similarly inhibited by TGF-β1 in both types of cells, results that are consistent with the microarray data. In addition, the inducibility of PAI-1 expression, a TGF-β1 target gene known to be regulated by the Smad pathway [Dong et al. 2001], was unaffected by LEF1ΔC expression [Fig. 4I], supporting the notion that LEF1ΔC expression only affects selected TGF-β-responsive genes in MSCs. Thus, although the expression of LEF1ΔC as a dominant-negative inhibitor to block β-catenin nuclear translocation could have unknown effects, taken together, these results suggest that this β-catenin-mediated TGF-β1 signaling pathway regulates the expression of specific target genes without affecting the expression pattern of other genes that are likely under the sole control of Smad proteins.

Discussion

In this study, we demonstrated the existence of a novel form of cross-talk between the TGF-β and Wnt signaling pathways. We have shown that TGF-β1-induced β-catenin nuclear translocation is mediated by a novel mechanism that is independent of changes in β-catenin stability and phosphorylation status. We have provided evidence that the effector of TGF-β signaling, Smad3, plays an essential role in shuffling β-catenin into the nucleus, likely through a TGF-β1-induced change in the dynamics and composition of protein complexes. In this model, the signaling process is initiated by the TGF-β receptor-mediated phosphorylation of Smad3, leading to the disruption of the protein complex as indicated by the reduced interactions between Smad3 and GSK-3β. Dissociation of this protein complex allows cotranslocation of β-catenin and Smad3 into the nucleus, with Smad3 acting as a chaperone, a scenario consistent with the constitutive interactions between the two proteins and the established rapid time course of Smad3 nuclear translocation.

It is intriguing that this novel signaling pathway is found in the MSCs but not other cell types examined, even though the interactions between Smad3, β-catenin, and other components of the Axin/CKI/GSK-3 complex have been documented in those cell types, suggesting that the cellular context of MSCs may be a prerequisite for the existence of the unique cross-talk between the two prominent signaling pathways. Furthermore, our studies show that TGF-β elicits unique biological effects in this specific cellular context of human MSCs, as it stimulates the proliferation of those cells [Fig. 3A], which is in contrast to the potent antiproliferative effect of TGF-β on many other cell types, suggesting that TGF-β1 may induce specific biological responses through the combined actions of β-catenin and Smad proteins in the nucleus to regulate the expression of a specific set of TGF-β1 target genes. It remains to be determined whether TCF/LEF transcription factors participate in the mediation of TGF-β-induced proliferative response in MSCs once β-catenin is cotranslocated with Smad3 into the nucleus. It is possible that the two sets of partners, β-catenin/Smad3 and β-catenin/TCF/LEF, act to regulate the expression of different target genes, and together they mediate the biological effects of TGF-β in this cellular context. In this regard, we found that activation of this unique pathway by TGF-β1 leads to a substantial increase in the expression of BLK, a member of the Src tyrosine kinase family that potently promotes pre-B-cell leukemia development when its kinase activity is constitutively activated [Malek et al. 1998]. Although further experiments are necessary to demonstrate a causative relationship, this result suggests that the induction of BLK by the β-catenin/Smad3-mediated signaling pathway may be directly linked to the stimulatory effect of this pathway on the proliferation of MSCs. In the meantime, the β-catenin-independent repression of BAX expression may also contribute to the execution of the biological program of TGF-β in MSCs by suppressing apoptosis [von Haefen et al. 2004]. MSCs have been shown to secrete proteins of the TGF-β superfamily, and expression of at least four different Wnt proteins was detected in those cells [data not shown], suggesting that these two signaling pathways are likely involved in regulating the biological activities of MSCs. With the recent discovery that the Wnt signaling pathway plays an important role in the regulation of self-renewal of hematopoietic stem cells [Reya et al. 2003], subsequent research on the molecular composition of MSCs that permits the existence of this distinct TGF-β signaling pathway and on the functional characterization of downstream targets of this unique pathway should provide critical insights into the mechanisms underlying self-renewal and differentiation programs of MSCs.
Materials and methods

**Human MSCs**

Three separate batches of MSCs and growth medium were purchased from Cambrex Bio Science [PT-2501, PT-2506]. The cells were cultured according to the protocols provided by the manufacturer.

**Nuclear and cytoplasmic fractionation**

MSCs were added to buffer with PBS one time before collection by cytoplasmic lysis. Cells were lysed for 10 min on ice and then quick-spun for 15 sec to collect cytosolic lysates. Pellets were washed two times with cytoplasmic lysis buffer and then lysed with nuclear lysis buffer (10 mM Hepes at pH 7.9, 250 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP-40, 0.1% glycerol, 10 mM NaF, 10 mM Na3VO4, 1 mM DTT, 1x protease inhibitors, 0.5 mM PMSF) for 30 min on ice. The lysates were spun for 20 min at 14,000 rpm at 4°C to collect nuclear lysates. Lysates were run in SDS-PAGE for Western blot analysis.

**Immunofluorescence**

Immunofluorescence staining was carried out as described previously [Eckner et al. 1996].

**Osteogenic differentiation and ALP staining**

MSCs were cultured in OS medium for osteogenic differentiation. Osteogenic differentiation and ALP staining was performed according to the manual provided with the kit.

**Antibodies and immunoprecipitation**

Immunoprecipitation and Western blot were carried out as described [Shen et al. 1998]. Antibodies to β-catenin (Transduction Lab), GSK-3β (Santa Cruz), Smad1/5/8 (Santa Cruz), Smad3 (Zymed), Phospho-Smad2 (Cell Signaling), Lamin (Santa Cruz), β-tubulin (Santa Cruz), LEFI [Oncogene], HA Y-11 (Santa Cruz), and Mkc9E10 [Roche] were used to detect proteins and for immunoprecipitation. HRP-conjugated antibodies to mouse or rabbit IgG were purchased from Zymed.

**Quantitative real-time RT-PCR**

Real-time RT-PCR was performed as described [Bai et al. 2004]. GAPDH gene was used as the internal control for normalization. The primer sequences for BLK were as follows: forward, 5’-GCTGATGATTCGAGCCAAG-3’, and reverse, 5’-CTGCGATGATTCGAGCCCAAGC-3’. The primer sequences for BAX were as follows: forward, 5’-GCTGCATGATTCGAGCCCAAGC-3’, and reverse, 5’-ATTGCGATGATTCGAGCCCAAGC-3’. Standard curves for BLK and BAX primers were constructed using a serial dilution of cDNA to verify equal amplification efficiency.

**Microarray analysis**

The RNA samples used for microarray analysis were collected from vector control or LEF1ΔC-expressing MSCs untreated or treated with TGF-β for 2 h. The RNA samples were purified by RNeasy mini kit (Qiagen). For further information about preparation of the slides for microarrays, synthesis of fluorescent-labeled cDNA, hybridization, scanning and data acquisition, and quality control steps, visit the Duke University Microarray Core Facility at http://microarray.genome.duke.edu. Data were analyzed using GeneSpring 6.1 [Silicon Genetics].

**Acknowledgments**

We thank T. Reya, R. Wechsler-Reya, A.W. Duncan, D. Zhang, P. Casey, and D. Kaplan for various reagents, and J. Nevins and C. Counter for critically reading the manuscript. This work was supported by NIH grant DK064113 to X.F.W. and a DOD grant DAMD 17-02-1-0369 to H.J.

**References**

Bai, X., Alekseyenko, A.A., and Kuroda, M.I. 2004. Sequence-specific targeting of MSL complex regulates transcription of the roX RNA genes. *EMBO J.* 23: 2853–2861.

Barth, A.I., Stewart, D.B., and Nelson, W.J. 1999. T cell factor-activated transcription is not sufficient to induce anchorage-independent growth of epithelial cells expressing mutant β-catenin. *Proc. Natl. Acad. Sci.* 96: 4947–4952.

Cadigan, K.M. and Nusse, R. 1997. Wnt signaling: A common theme in animal development. *Genes & Dev.* 11: 3286–3305.

Caplan, A.I. 2000. Mesenchymal stem cells and gene therapy. *Clin. Orthop. Relat. Res.* 5–670–677.

Derynck, R., Zhang, Y., and Fong, X.H. 1998. Smads: Transcriptional activators of TGF-β responses. *Cell* 95: 737–740.

Dong, C., Zhu, S., Yoon, W., Wang, T., Alvarez, R.J., and Goldschmidt-Clermont, P.J. 2001. Upregulation of PAI-1 is mediated through TGF β/SMAD pathway in transplant arteriopathy. *J. Heart Lung Transplant.* 20: 219.

Eckner, R., Yao, T.P., Oldread, E., and Livingston, D.M. 1996. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. *Genes & Dev.* 10: 2478–2490.

Furuhashi, M., Yagi, K., Yamamoto, H., Furukawa, Y., Shimada, S., Nakamura, Y., Kikuchi, A., Miyazono, K., and Kato, M. 2001. Axin facilitates Smad3 activation in the transforming growth factor β signaling pathway. *Mol. Cell. Biol.* 21: 5132–5141.

He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B. 1998. A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci.* 95: 2509–2514.

He, X., Semenov, M., Tamai, K., and Zeng, X. 2004. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way. *Development* 131: 1663–1677.

Hino, S., Michiue, T., Asashima, M., and Kikuchi, A. 2003. Casein kinase 1ε enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of β-catenin. *J. Biol. Chem.* 278: 14066–14073.

Hsieh, J.C., Rattner, A., Smallwood, P.M., and Nathans, J. 1999. Biochemical characterization of Wnt–frizzled interactions using a soluble, biologically active vertebrate Wnt protein. *Proc. Natl. Acad. Sci.* 96: 3546–3551.

Labbe, E., Letamendia, A., and Attisano, L. 2000. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-β and wnt pathways. *Proc. Natl. Acad. Sci.* 97: 8358–8363.

Logan, C.Y. and Nusse, R. 2004. The Wnt signaling pathway in β-catenin mediates TGF-β activity in hMSCs.
development and disease. Annu. Rev. Cell Dev. Biol. 20: 781–810.

Malek, S.N., Dordai, D.I., Reim, J., Dintzis, H., and Desiderio, S. 1998. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc. Natl. Acad. Sci. 95: 7351–7356.

Massague, J. 1998. TGF-β signal transduction. Annu. Rev. Biochem. 67: 753–791.

Nishita, M., Hashimoto, M.K., Ogata, S., Laurent, M.N., Ueno, N., Shibuya, H., and Cho, K.W. 2000. Interaction between Wnt and TGF-β signalling pathways during formation of Spemann's organizer. Nature 403: 781–785.

Orford, K., Crockett, C., Jensen, J.P., Weissman, A.M., and Byers, S.W. 1997. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J. Biol. Chem. 272: 24735–24738.

Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143–147.

Prieve, M.G., Guttridge, K.L., Munguia, J.E., and Waterman, M.L. 1996. The nuclear localization signal of lymphoid enhancer factor-1 is recognized by two differentially expressed Srp1-nuclear localization sequence receptor proteins. J. Biol. Chem. 271: 7654–7658.

Reya, T., Duncan, A.W., Ailles, L., Domeng, J., Scherer, D.C., Willert, K., Hintz, L., Nusse, R., and Weissman, I.L. 2003. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423: 409–414.

Shen, X., Hu, P.P., Liberati, N.T., Datto, M.B., Frederick, J.P., and Wang, X.F. 1998. TGF-β-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol. Biol. Cell 9: 3309–3319.

Tuli, R., Tuli, S., Nandi, S., Huang, X., Manner, P.A., Hozack, W.J., Danielson, K.G., Hall, D.J., and Tuan, R.S. 2003. Transforming growth factor-β-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J. Biol. Chem. 278: 41227–41236.

Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J.Y., Almirez, R., Mangadu, R., Liu, Y.W., Platten, M., Herrlinger, U., et al. 2004. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64: 7954–7961.

van de Wetering, M., Oving, I., Muncan, V., Pon Fong, M.T., Brantjes, H., van Leenen, D., Holstege, F.C., Brummelkamp, T.R., Agami, R., and Clevers, H. 2003. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 4: 609–615.

von Haefen, C., Gillissen, B., Hemmati, P.G., Wendt, J., Guner, D., Mrozek, A., Belka, C., Dorken, B., and Daniel, P.T. 2004. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23: 8320–8332.

Waddell, D.S., Liberati, N.T., Guo, X., Frederick, J.P., and Wang, X.F. 2004. Casein kinase Iε plays a functional role in the transforming growth factor-β signaling pathway. J. Biol. Chem. 279: 29236–29246.

Zhou, S., Eid, K., and Glowacki, J. 2004. Cooperation between TGF-β and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J. Bone Miner. Res. 19: 463–470.
Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells

Hongyan Jian, Xing Shen, Irwin. Liu, et al.

Genes Dev. 2006, 20:
Access the most recent version at doi:10.1101/gad.1388806

Supplemental Material
http://genesdev.cshlp.org/content/suppl/2006/03/01/20.6.666.DC1

References
This article cites 27 articles, 18 of which can be accessed free at:
http://genesdev.cshlp.org/content/20/6/666.full.html#ref-list-1

License

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.